



Supporting Information

for

Synthesis and selected transformations of 2-unsubstituted 1-(adamantyloxy)imidazole 3-oxides: straightforward access to non-symmetric 1,3-dialkoxyimidazolium salts

Grzegorz Młostoń, Małgorzata Celeda, Katarzyna Urbaniak, Marcin Jasiński,
Vladyslav Bakhonsky, Peter R. Schreiner and Heinz Heimgartner

Beilstein J. Org. Chem. **2019**, *15*, 497–505. doi:10.3762/bjoc.15.43

Experimental and analytical data and copies of NMR spectra

Preparation of methylidene(adamantyl-1-oxy)amine (6a): To a solution of **4** (1.01 g, 6 mmol) in 20 mL of MeOH, paraformaldehyde (197 mg, 6.55 mmol) was added, and the mixture was heated to reflux for 1 h. Then, the solution was filtered and the clear filtrate was evaporated to dryness. Yield of **6a**: 961 mg (90%); mp 55–58 °C. An analytically pure sample was obtained by crystallization from diisopropyl ether after cooling in dry ice container. Colorless crystals; mp 61–62 °C; ¹H NMR δ 1.60, 1.69 (AB-system, $J_{H,H} = 12.0$ Hz, 6H, 3CH₂(ad)), 1.84 (br. s, 6H, 3CH₂(ad)), 2.16 (br. s, 3H, 3CH(ad)), 6.39, 7.01 (AB-system, $J_{H,H} = 12$ Hz, =CH₂) ppm; ¹³C NMR δ 30.6 (3CH(ad)), 36.4 (3CH₂(ad)), 41.4 (3CH₂(ad)), 77.7 (C_q(ad)-O), 136.1 (N=CH₂) ppm; IR: ν 2905vs, 2851s, 1612w (C=N), 1483m, 1351m, 1108m, 1078vs, 948br.vs, 862s, 812w cm⁻¹; anal. calcd for C₁₁H₁₇NO (179.26): C, 73.70; H, 9.56; N, 7.81; found: C, 73.86; H, 9.59; N, 7.90.

Imidazole *N*-oxides **7b–e**:

1-Adamantyloxy-4,5-diphenylimidazole 3-oxide (7b)·H₂O: Yield: 380 mg (98%). Pale yellow crystals; mp 137–138 °C; ¹H NMR δ 1.46, 1.57 (AB-system, $J_{H,H} = 12.5$ Hz, 6H, 3CH₂(ad)), 1.60 (pseudo d, $J_{H,H} = 2.5$ Hz, 6H, 3CH₂(ad)), 2.13 (brs, 3H, 3CH(ad)), 7.32–7.38 (m, 8CH_{arom}), 7.55–7.57 (m, 2CH_{arom}), 8.10 (s, HC(2)) ppm; ¹³C NMR δ 30.9 (3CH(ad)), 35.4, 40.6 (6CH₂(ad)), 88.4 (C_q(ad)-O), 124.3, 125.7, 126.4, 126.8, 127.2 (2C_{arom}, 2C=, HC(2)), 128.3, 128.5, 128.6, 129.1, 130.3, 130.4 (10CH_{arom}) ppm; IR: ν 2913s, 2853m, 1507m, 1448m, 1381m, 1358m, 1192m, 1045s, 883s, 857s, 762vs, 691vs, 599m cm⁻¹; anal. calcd for C₂₅H₂₆N₂O₂·H₂O (404.49): C, 74.23; H, 6.98; N, 6.92; found: C, 73.86; H, 7.03; N, 6.79.

1-Adamantyloxy-5-methyl-4-phenylimidazole 3-oxide (7c): Yield: 200 mg (62%). Pale yellow crystals; mp 121–122 °C; ¹H NMR δ 1.44, 1.55 (AB-system, $J_{H,H} = 12.5$ Hz, 6H, 3CH₂(ad)), 1.57 (pseudo d, $J_{H,H} = 2.7$ Hz, 6H, 3CH₂(ad)), 2.10 (brs, 3H, 3CH(ad)), 2.34 (s, 3H, CH₃), 7.46–7.48 (m, 2CH_{arom}), 7.49–7.51 (m, 3CH_{arom}), 7.97 (s, HC(2)) ppm; ¹³C NMR δ 7.9 (CH₃), 30.8 (3CH(ad)), 35.5, 40.6 (6CH₂(ad)), 87.9 (C_q(ad)-O), 123.5, 124.7, 125.1, 127.2 (C_{arom}, 2C=, HC(2)), 128.6, 128.8, 129.5

(5CH_{arom}) ppm; IR: ν 2906s, 2851m, 1584m, 1444m, 1354s, 1232m, 1127m, 1053s, 900s, 857m, 768vs, 724vs, 602s cm⁻¹; anal. calcd for C₂₀H₂₄N₂O₂ (324.42): C, 74.04; H, 7.46; N, 8.64; found: C, 74.04; H, 7.34; N, 8.76.

1-Adamantyloxy-4-methyl-5-phenylimidazole 3-oxide (7d): Yield: 270 mg (83%). Pale yellow crystals; mp 130–132 °C; ¹H NMR δ 1.63, 1.72 (AB-system, J_{H,H} = 12.5 Hz, 6H, 3CH₂(ad)), 1.93 (pseudo d, J_{H,H} = 2.7 Hz, 6H, 3CH₂(ad)), 2.30 (s, 3H, CH₃), 2.32 (brs, 3H, 3CH(ad)), 7.37–7.40 (m, 1CH_{arom}), 7.70–7.72 (m, 2CH_{arom}), 7.97 (s, HC(2)) ppm; ¹³C NMR δ 9.5 (CH₃), 30.9 (3CH(ad)), 35.6, 40.8 (6CH₂(ad)), 87.4 (C_q(ad)-O), 122.4, 123.8, 126.9, 127.1 (C_{arom}, 2C=, HC(2)), 128.3, 128.4, 129.5 (5CH_{arom}) ppm; IR: ν 2906s, 2851m, 1584m, 1496m, 1444m, 1354s, 1235m, 1127m, 1053s, 900s, 857m, 769vs, 698vs, 598s cm⁻¹; anal. calcd for C₂₀H₂₄N₂O₂ (324.42): C, 74.04; H, 7.46; N, 8.64; found: C, 74.01; H, 7.46; N, 8.75.

1-Adamantyloxy-4-[(4-bromophenyl)carbamoyl]-5-methylimidazole hydrochloride (7e)·0.5H₂O: Yield: 224 mg (50%). Pale yellow crystals; mp 197–199 °C; ¹H NMR δ 1.62, 1.71 (AB-system, J_{H,H} = 12.4 Hz, 6H, 3CH₂(ad)), 1.89 (pseudo d, J_{H,H} = 2.7 Hz, 6H, 3CH₂(ad)), 2.32 (brs, 3H, 3CH(ad)), 2.63 (s, 3H, CH₃), 7.44, 7.60 (AB-system, J_{H,H} = 8.8 Hz, 4CH_{arom}), 7.99 (s, HC(2)), 12.90 (s, NH) ppm; ¹³C NMR δ 9.9 (CH₃), 31.0 (3CH(ad)), 35.5, 40.9 (6CH₂(ad)), 89.0 (C_q(ad)-O), 116.6, 119.0, 120.9, 123.8 (C_{arom}-Br, C_{arom}-N, 2C=), 122.0, 131.8 (4CH_{arom}), 157.3 (C=O) ppm; IR: ν 2909m, 2851m, 1675m (C=O), 1586m, 1552s, 1489s, 1314m, 1295m, 1049s, 821s, 803vs, 511s cm⁻¹; anal. calcd for C₂₁H₂₄BrN₃O₃·HCl·0.5H₂O (491.69): C, 51.28; H, 5.33; N, 8.54; found: C, 51.48; H, 5.48; N, 8.51.

Imidazoles 8b–d:

1-Adamantyloxy-4,5-diphenyl-1*H*-imidazole (8b): Yield: 244 mg (66%). Pale yellow crystals; mp 165–167 °C; ¹H NMR δ 1.47, 1.58 (AB-system, J_{H,H} = 11.9 Hz, 6H, 3CH₂(ad)), 1.59 (pseudo d, J_{H,H} = 2.6 Hz, 6H, 3CH₂(ad)), 2.11 (brs, 3H, 3CH(ad)), 7.21–7.22 (m, 1CH_{arom}), 7.27–7.29 (m, 2CH_{arom}), 7.37–7.42 (m, 3CH_{arom}), 7.46–7.48 (m, 2CH_{arom}), 7.55–7.57 (m, 2CH_{arom}), 7.68 (s, HC(2)) ppm; ¹³C NMR δ 30.8 (3CH(ad)), 35.7, 40.9 (6CH₂(ad)), 85.7 (C_q(ad)-O), 127.1, 128.2, 128.4, 130.6, 133.9

($10\text{CH}_{\text{arom}}$), 127.0, 128.1, 129.7, 129.1, 134.8 (2C_{arom} , $2\text{C}=\text{}$, $\text{HC}(2)$) ppm; IR: ν 2918s, 2853m, 1505m, 1457m, 1440m, 1353m, 1057s, 941s, 747s, 695vs, 587s cm^{-1} ; HRMS (ESI $^+$): calcd. for $[\text{C}_{20}\text{H}_{27}\text{N}_2\text{O}]^+$: 371.2123; found 371.2126.

1-Adamantyloxy-5-methyl-4-phenyl-1*H*-imidazole (8c): Yield: 191 mg (62%). Pale yellow crystals; mp 105–107 °C; ^1H NMR δ 1.44, 1.54 (AB-system, $J_{\text{H},\text{H}} = 12.0$ Hz, 6H, 3CH₂(ad)), 1.58 (pseudo d, $J_{\text{H},\text{H}} = 2.4$ Hz, 6H, 3CH₂(ad)), 2.08 (brs, 3H, 3CH(ad)), 2.32 (s, 3H, CH₃), 7.32–7.33 (m, 1CH_{arom}), 7.41–7.44 (m, 2CH_{arom}), 7.47–7.49 (m, 2CH_{arom}), 7.51 (s, HC(2)) ppm; ^{13}C NMR δ 14.4 (CH₃), 30.8 (3CH(ad)), 35.7, 40.8 (6CH₂(ad)), 85.4 (C_q(ad)-O), 127.1, 128.2, 129.2 (5CH_{arom}), 126.4, 130.0, 131.2, 132.8 (C_{arom}, 2C=, HC(2)) ppm; IR: ν 2909s, 2849m, 1604m, 1492m, 1449m, 1351s, 1052s, 1025s, 883s, 754vs, 697vs, 596s cm^{-1} ; anal. calcd for C₂₀H₂₄N₂O (308.42): C, 77.89; H, 7.84; N, 9.08; found: C, 77.85; H, 7.92; N, 9.10.

1-Adamantyloxy-4-methyl-5-phenyl-1*H*-imidazole (8d): Yield: 120 mg (39%). Pale yellow crystals; mp 105–108 °C; ^1H NMR δ 1.63, 1.70 (AB-system, $J_{\text{H},\text{H}} = 12.5$ Hz, 6H, 3CH₂(ad)), 1.93 (pseudo d, $J_{\text{H},\text{H}} = 2.6$ Hz, 6H, 3CH₂(ad)), 2.28 (brs, 3H, 3CH(ad)), 2.43 (s, 3H, CH₃), 7.37–7.40 (m, 1CH_{arom}), 7.40–7.42 (m, 2CH_{arom}), 7.54 (s, HC(2)), 7.73–7.74 (m, 2CH_{arom}) ppm; ^{13}C NMR δ 10.3 (CH₃), 30.9 (3CH(ad)), 35.8, 41.0 (6CH₂(ad)), 85.3 (C_q(ad)-O), 126.1, 126.2, 128.4 (5CH_{arom}), 122.8, 132.8, 132.9, 135.3 (C_{arom}, 2C=, HC(2)) ppm; IR: ν 2914s, 2853m, 1602m, 1498m, 1442m, 1351m, 1299m, 1047s, 924s, 887s, 767s, 700vs, 578m cm^{-1} ; HRMS (ESI $^+$): calcd. for [C₂₀H₂₅N₂O] $^+$: 309.1967; found 309.1974.

Isomerization of imidazole *N*-oxide 7b: A solution of 0.5 mmol (193 mg) of **7b** in 2 mL of CHCl₃ was stirred magnetically at rt and 0.25 mL of acetic anhydride was added drop-wise. The obtained solution was stirred overnight. Then, the solvent was evaporated and the solid residue was crystallized from a MeOH/CH₂Cl₂ mixture. The obtained crystals were filtered off and dried.

1-Adamantyloxy-4,5-diphenyl-3*H*-imidazol-2-one (9): Yield: 70 mg (36%). Colorless crystals; mp 119–120 °C; ^1H NMR δ 1.44, 1.46 (AB-system, $J_{\text{H},\text{H}} = 12.0$ Hz, 6H, 3CH₂(ad)), 1.67 (brs, 6H, 3CH₂(ad)), 2.03 (brs, 3H, 3CH(ad)), 7.15–7.45 (m,

10H, 2C₆H₅), 11.0 (brs, 1H, NH) ppm; ¹³C NMR δ 30.9 (3CH(ad)), 35.8 (3CH₂(ad)), 40.8 (3CH₂(ad)), 86.0 (C_q(ad)-O), 115.0, 121.0 (2C (imidazol)), 126.3, 127.1, 128.3, 128.4, 128.5, 131.0 (10CH_{arom}), 129.1, 129.8 (2C_{arom}), 153.0 (C=O) ppm; IR: ν 2907m, 2849m, 2771 (br.m, NH), 1705vs (C=O), 1444m, 1354m, 1298w, 1056m, 905m, 773s, 732s, 707vs cm⁻¹; HRMS (ESI⁺): calcd. for [C₂₅H₂₇N₂O₂]⁺: 387.2073; found 387.2073.

1*H*-Imidazole-2(3*H*)-thiones 10b–d:

1-Adamantyloxy-4,5-diphenyl-1*H*-imidazole-2(3*H*)-thione (10b): Yield: 220 mg (55%). Pale yellow crystals; mp 163–165 °C; ¹H NMR δ 1.45, 1.50 (AB-system, J_{H,H} = 12.1 Hz, 6H, 3CH₂(ad)), 1.71–1.80 (brs, 6H, 3CH₂(ad)), 2.01 (brs, 3H, 3CH(ad)), 7.27–7.31 (m, 3CH_{arom}), 7.33–7.36 (m, 2CH_{arom}), 7.39–7.44 (m, 5CH_{arom}), 12.12 (brs, 1H, NH) ppm; ¹³C NMR δ 31.4 (3CH(ad)), 35.7, 41.6 (6CH₂(ad)), 90.3 (C_q(ad)-O), 127.3, 128.2, 128.6, 128.7, 129.2, 131.0 (10CH_{arom}), 122.3, 126.7, 128.0, 129.1 (2C_{arom}, 2C=), 159.7 (C=S) ppm; IR: ν 3062m, 2907s, 2849m, 1477s, 1448m, 1388m, 1353m, 1295s, 1049m, 877s, 900s, 733s, 695vs, 564m cm⁻¹; anal. calcd for C₂₅H₂₆N₂OS (402.55): C, 74.59; H, 6.51; N, 6.96; S, 7.97; found: C, 74.75; H, 6.79; N, 6.87; S, 7.78.

1-Adamantyloxy-5-methyl-4-phenyl-1*H*-imidazole-2(3*H*)-thione (10c): Yield: 300 mg (88%). Pale yellow crystals; mp 153–154 °C; ¹H NMR δ 1.45, 1.50 (AB-system, J_{H,H} = 12.2 Hz, 6H, 3CH₂(ad)), 1.78 (pseudo d, J_{H,H} = 2.2 Hz, 6H, 3CH₂(ad)), 2.05 (brs, 3H, 3CH(ad)), 2.22 (s, 3H, CH₃), 7.35–7.39 (m, 1CH_{arom}), 7.42–7.45 (m, 4CH_{arom}), 12.49 (brs, 1H, NH) ppm; ¹³C NMR δ 10.1 (CH₃), 31.3 (3CH(ad)), 35.7, 41.6 (6CH₂(ad)), 90.0 (C_q(ad)-O), 119.0, 126.7, 128.2 (C_{arom}, 2C=), 128.3, 128.4, 129.7 (5CH_{arom}), 157.7 (C=S) ppm; IR: ν 3062m, 2905s, 2851m, 1502s, 1478m, 1448m, 1377m, 1297m, 1244m, 1042s, 977m, 933s, 756vs, 698vs, 575m cm⁻¹; HRMS (ESI⁺): calcd. for [C₂₀H₂₅N₂OS]⁺: 341.1688; found 341.1691.

1-Adamantyloxy-4-methyl-5-phenyl-1*H*-imidazole-2(3*H*)-thione (10d): Yield: 99 mg (29%). Pale yellow crystals; mp 165–166 °C; ¹H NMR δ 1.66 (pseudo t, J_{H,H} = 2.9 Hz, 6H, 3CH₂(ad)), 2.21 (pseudo d, J_{H,H} = 3.1 Hz, 6H, 3CH₂(ad)), 2.26 (brs, 3H, 3CH(ad)), 2.37 (s, 3H, CH₃), 7.31–7.34 (m, 1CH_{arom}), 7.43–7.46 (m, 2CH_{arom}), 7.50–

7.52 (m, 2CH_{arom}), 11.92 (brs, 1H, NH) ppm; ¹³C NMR δ 10.8 (CH₃), 31.5 (3CH(ad)), 35.8, 42.0 (6CH₂(ad)), 89.6 (C_q(ad)-O), 121.9, 122.9, 128.6 (C_{arom}, 2C=), 126.7, 127.9, 129.0 (5CH_{arom}), 159.2 (C=S) ppm; IR: ν 3049m, 2912s, 2848m, 1569m, 1489m, 1433m, 1357m, 1297m, 1244m, 1041s, 881s, 933s, 756vs, 698vs, 525m cm⁻¹; anal. calcd for C₂₀H₂₄N₂OS (340.48): C, 70.55; H, 7.10; N, 8.23; S, 9.42; found: C, 70.56; H, 7.08; N, 8.23; S, 9.50.

3-Alkoxyimidazolium bromides 13b–g:

1-Adamantyloxy-3-dodecyloxy-4,5-dimethyl-1*H*-imidazolium bromide (13b):

Yield: 415 mg (81%). Pale yellow crystals; mp 116 °C (decomp.); ¹H NMR δ 0.94 (t, J_{H,H} = 6.9 Hz, 3H, CH₃(d)), 1.23–1.33 (m, 14H, 7CH₂(d)), 1.46–1.52 (m, 2H, CH₂(d)), 1.81–1.86 (m, 4H, 2CH₂(d)), 1.69 (brs, 6H, 3CH₂(ad)), 2.01 (pseudo d, J_{H,H} = 2.6 Hz, 6H, 3CH₂(ad)), 2.28 (s, 3H, CH₃-C=), 2.30 (s, 3H, CH₃-C=), 2.34 (brs, 3H, 3CH(ad)), 4.80 (t, J_{H,H} = 6.9 Hz, 2H, CH₂-O), 11.50 (s, HC(2)) ppm; ¹³C NMR δ 7.3, 8.3, 14.1 (3CH₃), 22.7, 25.6, 27.8, 29.3, 29.4, 29.5, 29.6, 29.7, 29.8, 31.9 (10CH₂(d)), 31.3 (3CH(ad)), 35.3, 40.8 (6CH₂(ad)), 83.9 (CH₂-O), 91.4 (C_q(ad)-O), 122.0, 123.7 (2C=), 131.4 (HC(2)) ppm; IR: ν 2914s, 2849s, 1638m, 1468m, 1399m, 1295m, 1049s, 1003m, 892s, 589s cm⁻¹; HRMS (ESI⁺): calcd. for [C₂₇H₄₇N₂O₂]⁺: 431.3638; found 431.3651.

1-Adamantyloxy-3-pentyloxy-4,5-diphenyl-1*H*-imidazolium bromide (13c): Yield:

425 mg (79%). Colorless crystals; mp 158 °C (decomp.); ¹H NMR δ 0.79 (t, J_{H,H} = 6.9 Hz, 3H, CH₃), 1.14–1.20 (m, 4H, 2CH₂(p)), 1.50–1.59 (m, 6H, 3CH₂(ad)), 1.65–1.68 (m, 2H, CH₂(p)), 1.74 (brd, 6H, 3CH₂(ad)), 2.19 (brs, 3H, 3CH(ad)), 4.61 (t, J_{H,H} = 7.0 Hz, 2H, CH₂-O), 7.38–7.53 (m, 10CH_{arom}), 12.12 (s, HC(2)) ppm; ¹³C NMR δ 13.7 (CH₃), 22.1, 27.3, 27.4 (3CH₂(p)), 31.2 (3CH(ad)), 35.3, 40.5 (6CH₂(ad)), 84.3 (CH₂-O), 92.3 (C_q(ad)-O), 122.7, 123.9, 125.8, 127.9 (2C_{arom}, 2C=), 129.1, 129.2, 130.2, 130.4, 130.6, 130.7 (10CH_{arom}), 132.8 (HC(2)) ppm; IR: ν 3035m, 2914m, 2853m, 1647m, 1448m, 1358m, 1295m, 1053s, 967s, 793s, 589s cm⁻¹; anal. calcd for C₃₀H₃₇BrN₂O₂ (536.20): C, 67.03; H, 6.94; N, 5.21; found: C, 67.20; H, 7.04; N, 5.25.

1-Adamantyl-4,5-dimethyl-3-pentyloxy-1*H*-imidazolium bromide (13d): Yield: 310 mg (78%). Semi-solid beige crystals; ^1H NMR δ 0.90 (t, $J_{\text{H},\text{H}} = 7.3$ Hz, 3H, $\text{CH}_3(\text{p})$), 1.31–1.42 (m, 2H, $\text{CH}_2(\text{p})$), 1.43–1.49 (m, 2H, $\text{CH}_2(\text{p})$), 1.73 (pseudo t, 6H, 3 $\text{CH}_2(\text{ad})$), 1.80–1.87 (m, 2H, $\text{CH}_2(\text{p})$), 2.23 (s, 3H, $\text{CH}_3-\text{C}=\text{}$), 2.29 (brs, 3H, 3 $\text{CH}(\text{ad})$), 2.33 (s, 6H, $\text{CH}_2(\text{ad})$), 2.46 (s, 3H, $\text{CH}_3-\text{C}=\text{}$), 4.69 (t, $J_{\text{H},\text{H}} = 6.7$ Hz, 2H, CH_2-O), 10.24 (brs, 1H, $\text{HC}(2)$) ppm; ^{13}C NMR δ 7.1 (CH_3), 12.6, 13.8 (2 $\text{CH}(\text{ad})$), 22.4, 27.5, 27.6 (3 $\text{CH}_2(\text{p})$), 29.6 ($\text{CH}(\text{ad})$), 35.3 (3 $\text{CH}_2(\text{ad})$), 41.6 (3 $\text{CH}_2(\text{ad})$), 64.0 ($\text{C}(\text{ad})-\text{N}$), 83.4 (CH_2-O), 123.6, 125.7 (2 $\text{C}=\text{}$), 131.4 ($\text{HC}(2)$) ppm; IR: ν 2913s, 2855s, 1451m, 1304m, 983s, 723vs, 625m cm^{-1} ; HRMS (ESI $^+$): calcd. for $[\text{C}_{20}\text{H}_{33}\text{N}_2\text{O}]^+$: 317.2593; found 317.2605.

1-Adamantyl-3-dodecyloxy-4,5-dimethyl-1*H*-imidazolium bromide (13e): Yield: 370 mg (75%). Beige crystals; mp 100–104 °C; ^1H NMR δ 0.88 (t, $J_{\text{H},\text{H}} = 6.8$ Hz, 3H, $\text{CH}_3(\text{d})$), 1.26–1.34 (m, 16H, 8 $\text{CH}_2(\text{d})$), 1.46–1.49 (m, 2H, $\text{CH}_2(\text{d})$), 1.75–1.79 (m, 6H, 3 $\text{CH}_2(\text{ad})$), 1.81–1.86 (m, 2H, $\text{CH}_2(\text{d})$), 2.25 (s, 3H, $\text{CH}_3-\text{C}=\text{}$), 2.33 (brs, 3H, 3 $\text{CH}(\text{ad})$), 2.38 (s, 6H, $\text{CH}_2(\text{ad})$), 2.48 (s, 3H, $\text{CH}_3-\text{C}=\text{}$), 4.78 (t, $J_{\text{H},\text{H}} = 6.5$ Hz, 2H, CH_2-O), 10.24 (brs, 1H, $\text{HC}(2)$) ppm; ^{13}C NMR δ 7.0, 12.5, 14.2 (3 CH_3), 25.6, 27.6, 27.9, 29.0, 29.3, 29.4, 29.5, 29.7, 29.8 (10 $\text{CH}_2(\text{d})$), 31.9 (3 $\text{CH}(\text{ad})$), 35.3, 41.6 (6 $\text{CH}_2(\text{ad})$), 64.1 ($\text{C}_q(\text{ad})-\text{N}$), 83.5 (CH_2-O), 123.3, 125.6 (2 $\text{C}=\text{}$), 131.7 ($\text{HC}(2)$) ppm; IR: ν 2918s, 2849s, 1531m, 1453m, 1306m, 1226m, 1187m, 1076m, 944m, 635m cm^{-1} ; anal. calcd for $\text{C}_{27}\text{H}_{47}\text{BrN}_2\text{O}$ (495.58): C, 65.44; H, 9.56; N, 5.65; found: C, 65.65; H, 9.62; N, 5.86.

1-Adamantyl-3-pentyloxy-4,5-diphenyl-1*H*-imidazolium bromide (13f): Yield: 400 mg (77%). Beige crystals; mp 181 °C (dec.); ^1H NMR δ 0.78 (t, $J_{\text{H},\text{H}} = 6.8$ Hz, 3H, CH_3), 1.13–1.19 (m, 4H, 2 $\text{CH}_2(\text{p})$), 1.59–1.65 (m, 6H, 3 $\text{CH}_2(\text{ad})$), 1.78 (brs, 2H, $\text{CH}_2(\text{p})$), 2.18 (brs, 3H, 3 $\text{CH}(\text{ad})$), 2.33 (brs, 6H, 3 $\text{CH}_2(\text{ad})$), 4.63 (t, $J_{\text{H},\text{H}} = 6.8$ Hz, 2H, CH_2-O), 7.29–7.51 (m, 10 CH_{arom}), 10.68 (s, $\text{HC}(2)$) ppm; ^{13}C NMR δ 13.8 (CH_3), 22.1, 27.4 (3 $\text{CH}_2(\text{p})$), 29.8 (3 $\text{CH}(\text{ad})$), 35.3, 42.6 (6 $\text{CH}_2(\text{ad})$), 66.6 ($\text{C}_q(\text{ad})-\text{N}$), 83.5 (CH_2-O), 128.6, 128.7, 129.8, 130.1, 130.7, 132.5 (10 CH_{arom}), 123.1, 127.5 130.1, 130.7 (2 C_{arom} , 2 $\text{C}=\text{}$), 132.7 ($\text{HC}(2)$) ppm; IR: ν 2938s, 2854s, 1525m, 1499m, 1445m, 1365m, 1325m, 1246m, 1167m, 1147m, 987m, 763s, 696s cm^{-1} ; anal. calcd for $\text{C}_{30}\text{H}_{37}\text{BrN}_2\text{O}$ (520.21): C, 69.09; H, 7.15; N, 5.37; found: C, 69.11; H, 7.05; N, 5.30.

1-Adamantyl-3-dodecyloxy-4,5-diphenyl-1*H*-imidazolium bromide (13g): Yield: 460 mg (74%). Beige colored powder; mp 73–75 °C; ¹H NMR δ 0.83 (t, *J*_{H,H}= 6.6 Hz, 3H, CH₃(d)), 1.03–1.23 (m, 20H, 10CH₂(d)), 1.53–1.59 (m, 6H, 3CH₂(ad)), 2.12 (brs, 3H, 3CH(ad)), 2.28 (pseudo d, *J*_{H,H} = 1.9 Hz, 6H, 3CH₂(d)), 4.55 (t, *J*_{H,H} = 6.5 Hz, CH₂-O), 7.21–7.42 (m, 10CH_{arom}), 10.6 (brs, HC(2)) ppm; ¹³C NMR δ 14.0 (CH₃), 22.6, 25.3, 27.7, 29.1, 29.3, 29.4, 29.8, 31.9, 32.8, 34.0 (10CH₂(d)), 30.1 (3CH(ad)), 35.0, 42.5 (6CH₂(ad)), 66.5 (C(ad)-N), 83.5 (CH₂-N), 123.0, 127.3, 130.1, 130.5 (2C_{arom}, 2C=), 128.6, 128.7, 129.8, 130.7, 132.4 (10CH_{arom}), 132.5 (HC(2)) ppm; IR: ν 2918s, 2853s, 1521*m*, 1457*m*, 1306*m*, 1228*m*, 1167*m*, 1021*m*, 940*m*, 783s, 699vs cm⁻¹; anal. calcd for C₃₇H₅₁BrN₂O (619.72): C, 71.71; H, 8.29; N, 4.52; found: C, 71.45; H, 8.31; N, 4.21.

Attempted O-adamantylation of imidazole N-oxide 7a with adamantan-1-yl trifluoroacetate: In a 5 mL round bottom flask, imidazole N-oxide **7a** (131.0 mg, 0.5 mmol) was treated with a 5-fold excess of freshly prepared adamantan-1-yl trifluoroacetate (617 mg) and the obtained slurry was stored at rt overnight. The next day, the semi-solid material was triturated with 5 mL of pentane and the crystalline product **14** formed was filtered off. The filtrate was cooled in a refrigerator, and next day the separated white crystals of adamantan-1-ol (45 mg, 52%) were filtered off and identified by comparison with an original sample.

1-Adamantyloxy-3-hydroxy-4,5-dimethyl-1*H*-imidazolium trifluoroacetate (14): Yield: 115 mg (62%). Colorless crystals; mp 165 °C (dec.); ¹H NMR δ 1.64, 1.72 (AB-system, *J*_{H,H} = 12.0 Hz, 6H, 3CH₂(ad)), 1.90 (pseudo d, *J*_{H,H} = 2.6 Hz, 6H, 3CH₂(ad)), 2.24, 2.27 (2s, 6H, 2CH₃), 2.27 (brs, 3H, 3CH(ad)), 8.70 (s, 1H, HC(2)) ppm; ¹³C NMR δ 7.2, 8.3 (2CH₃), 31.1 (3CH(ad)), 35.4, 40.6 (6CH₂(ad)), 89.8 (C_q(ad)-O), 116.0 (q, ¹J_{C,F} = 289.4 Hz, CF₃), 122.6, 123.7, 126.3 (2C=, HC(2)), 161.6 (q, ²J_{C,F} = 36.1 Hz, C=O) ppm; IR: ν 2917s, 2853w, 1741*m*, br., 1364*m*, 1166vs, 1116vs, 1086s, 1040s, 875*m*, 616*m*, 715vs, 551*m*, 464*m* cm⁻¹; anal. calcd for C₁₇H₂₃F₃N₂O₄ (376.37): C, 54.25; H, 6.16; N, 7.44; found: C, 54.14; H, 6.30; N, 7.40.

Trapping of the in situ generated 1,3-di(adamantyloxy)imidazole-2-ylidene 16 with elemental sulfur: A solution of imidazolium salt **15** (449 mg, 1 mmol) in 10 mL

of dry pyridine was treated with 100 mg (1 mmol) triethylamine and elemental sulfur 32 mg (1 mmol). The solution was stirred magnetically at rt for 1 h and the solvents were evaporated in vacuo. The residue obtained thereafter was separated on preparative plates (SiO_2) using dichloromethane as an eluent. The isolated product was purified by crystallization from petroleum ether with a small amount of dichloromethane.

1,3-Di(adamantyloxy)-1*H*-imidazole-2(3*H*)-thione (17): Yield: 330 mg (83%). Pale yellow crystals; mp = 171–173 °C; ^1H NMR δ 1.59–1.69 (*m*, 3 CH_2 (ad)), 2.06 (*pseudo d*, $J_{\text{H,H}} = 2.6$ Hz, 6H, 3 CH_2 (ad)), 2.26 (*brs*, 3H, 3CH(ad)), 6.69 (*brs*, 2H, H(4) and H(5)); ^{13}C NMR δ 31.0 (3CH(ad)), 35.9, 41.4 (6 CH_2 (ad)), 87.9 (C_q(ad)-O), 114.6 (C(4), C(5)), 161.9 (C=S); IR: ν 3058*m*, 2903*s*, 2849*m*, 1448*m*, 1388*s*, 1351*s*, 1293*m*, 1244*m*, 1187*m*, 1049*s*, 998*s*, 810*m*, 676*vs*, 570*m*; anal. calcd for $\text{C}_{23}\text{H}_{32}\text{N}_2\text{O}_2\text{S}$ (400.58): C, 68.96; H, 8.05; N, 6.99; S, 8.00; found: C, 68.77; H, 8.18; N, 7.06; S, 7.94.

Collected ^1H and ^{13}C NMR spectra for compounds 6, 7, 8, 10, 13, 14, and 15




Fig. S1a. The ^1H NMR spectrum for compound **6a**.




Fig. S1b. The ^{13}C NMR spectrum for compound **6a**.




Fig. S2a. The ¹H NMR spectrum for compound 7a.




Fig. S2b. The ¹³C NMR spectrum for compound 7a.




Fig. S3a. The ^1H NMR spectrum for compound **7b**.




Fig. S3b. The ^{13}C NMR spectrum for compound **7b**.




Fig. S4a. The ^1H NMR spectrum for compound **7c**.




Fig. S4b. The ^{13}C NMR spectrum for compound **7c**.




Fig. S5a. The ^1H NMR spectrum for compound **7d**.




Fig. S5b. The ^{13}C NMR spectrum for compound **7d**.




Fig. S6a. The ^1H NMR spectrum for compound **7e**.




Fig. S6b. The ^{13}C NMR spectrum for compound **7e**.




Fig. S7a. The ¹H NMR spectrum for compound 8a.




Fig. S7b. The ¹³C NMR spectrum for compound 8a.




Fig. S8a. The ^1H NMR spectrum for compound **8b**.




Fig. S8b. The ^{13}C NMR spectrum for compound **8b**.




Fig. S9a. The ^1H NMR spectrum for compound **8c**.




Fig. S9b. The ^{13}C NMR spectrum for compound **8c**.




Fig. S10a. The ^1H NMR spectrum for compound **8d**.





Fig. S10b. The ^{13}C NMR for compound **8d**.






Fig. S12a. The ^1H NMR spectrum for compound **10b**.




Fig. S12b. The ^{13}C NMR spectrum for compound **10b**.




Fig. S13a. The ¹H NMR spectrum for compound 10c.




Fig. S13b. The ¹³C NMR spectrum for compound 10c.




Fig. S14a. The ^1H NMR spectrum for compound **10d**.






Fig. S14b. The ^{13}C NMR spectrum for compound **10d**.






Fig. S16a. The ¹H NMR spectrum for compound **13b**.




Fig. S16b. The ¹³C NMR spectrum for compound **13b**.




Fig. S17a. The ^1H NMR spectrum for compound **13c**.




Fig. S17b. The ^{13}C NMR spectrum for compound **13c**.




Fig. S18a. The ¹H NMR spectrum for compound 13d.




Fig. S18b. The ¹³C NMR spectrum for compound 13d.




Fig. S19a. The ^1H NMR spectrum for compound **13e**.




Fig. S19b. The ^{13}C NMR spectrum for compound **13e**.




Fig. S20a. The ¹H NMR spectrum for compound 13f.




Fig. S20b. The ¹³C NMR spectrum for compound 13f.




Fig. S21a. The ^1H NMR spectrum for compound 13g.




Fig. S21b. The ^{13}C NMR spectrum for compound 13g.




Fig. S22a. The ^1H NMR spectrum for compound 14.




Fig. S22b. The ^{13}C NMR spectrum for compound 14.




Fig. S23a. The ^1H NMR spectrum for compound 15.




Fig. S23b. The ^{13}C NMR spectrum for compound 15.